Frequency of Tuberculosis in Psoriasis Patients

Frequency of Tuberculosis in Psoriasis Patients Using Anti-TNF Therapy During 15 Years of Follow-up.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06563635

Enrollment

719

Registered

2024-08-21

Start date

2023-05-01

Completion date

2023-07-31

Last updated

2024-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis Vulgaris, Tuberculosis

Keywords

psoriasis, tnf inhibitor, tuberculosis

Brief summary

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center.

Detailed description

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center. TNF inhibitor therapy may increase the risk for tuberculosis infection. According to medical data in our hospital in last 15 years, tuberculosis rate of psoriasis patients receiving etanercept, adalimumab and infliximab will be compared.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Inclusion criteria

* psoriasis patients receiving TNF inhibitor therapy

Exclusion criteria

* patients without TNF inhibitor therapy

Design outcomes

Primary

Measure	Time frame	Description
tuberculosis rate	patients from June 2007 to January 2023, up to 15 years	number of patients with tuberculosis infection after receiving TNF inhibitor therapy

Countries

Turkey (Türkiye)

Outcome results